Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
As 'lower than projected' data send it back to the drawing board, Sanofi takes $1.6B hit on IL-2
One of the key programs that inspired Sanofi’s $2.5 billion buyout of Synthorx in late 2019 is now the subject of a $1.6 billion writedown …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
